Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial"

B Noiret¹, N Bakrin^{2

3}, C Eveno^{4

5}

Affiliations

¹ Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France.
² Department of Surgical Oncology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
³ EMR 3738, Faculte de Medecine et de Maieutique Lyon-Sud Charles Merieux, Lyon 1 University, Lyon, France.
⁴ Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France. clarisse.eveno@chru-lille.fr.
⁵ UMR-S1277 - CANTHER Laboratory "Cancer Heterogeneity, Plasticity and Resistance to Therapies", Lille, France. clarisse.eveno@chru-lille.fr.

Comment

B Noiret et al. Ann Surg Oncol. 2022 May.

. 2022 May;29(5):3357-3358.

doi: 10.1245/s10434-022-11434-2. Epub 2022 Feb 22.

B Noiret¹, N Bakrin^{2

3}, C Eveno^{4

5}

¹ Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France.
² Department of Surgical Oncology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
³ EMR 3738, Faculte de Medecine et de Maieutique Lyon-Sud Charles Merieux, Lyon 1 University, Lyon, France.
⁴ Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France. clarisse.eveno@chru-lille.fr.
⁵ UMR-S1277 - CANTHER Laboratory "Cancer Heterogeneity, Plasticity and Resistance to Therapies", Lille, France. clarisse.eveno@chru-lille.fr.

No abstract available

Comment in

Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
Cascales Campos PA, González Gil A. Cascales Campos PA, et al. Ann Surg Oncol. 2022 May;29(5):3361-3362. doi: 10.1245/s10434-022-11501-8. Epub 2022 Mar 7. Ann Surg Oncol. 2022. PMID: 35254577 No abstract available.

Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial.
Antonio CCP, Alida GG, Elena GG, Rocío GS, Jerónimo MG, Luis ARJ, Aníbal ND, Francisco BV, Jesús GRÁ, Pablo RR, José GM. Antonio CCP, et al. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. Ann Surg Oncol. 2022. PMID: 34812982 Clinical Trial.

1. Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2021. DOI: https://doi.org/10.1245/s10434-021-11087-7 .
1. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40. - DOI
1. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28. - DOI
1. Mahner S, Eulenburg C, Staehle A, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49:142–9. - DOI